1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Solstas Lab Partners

Anonymous boards for Solstas Lab Partners

Sort By:
Title
Replies Views
Last Message ↓
  1. Anonymous
    Replies:
    19
    Views:
    4,886
  2. Anonymous
    Replies:
    82
    Views:
    23,073
  3. Anonymous
    Replies:
    15
    Views:
    7,015
  4. Anonymous
    Replies:
    64
    Views:
    16,611
  5. Anonymous
    Replies:
    153
    Views:
    66,862
  6. Anonymous
    Replies:
    6
    Views:
    5,401
  7. anonymous
    Replies:
    2
    Views:
    2,149
  8. Anonymous
    Replies:
    48
    Views:
    11,484
  9. anonymous
    Replies:
    2
    Views:
    1,698
  10. Anonymous
    Replies:
    87
    Views:
    34,820
  11. Anonymous
    Replies:
    6
    Views:
    2,133
  12. Anonymous
    Replies:
    2
    Views:
    4,026
  13. Anonymous
    Replies:
    0
    Views:
    2,115
  14. Anonymous
    Replies:
    0
    Views:
    1,704
  15. Anonymous
    Replies:
    0
    Views:
    1,636
  16. Anonymous
    Replies:
    2
    Views:
    1,882
  17. Anonymous
    Replies:
    0
    Views:
    2,062
  18. Anonymous
    Replies:
    4
    Views:
    3,155
  19. Anonymous
    Replies:
    1
    Views:
    1,929
  20. Anonymous
    Replies:
    1
    Views:
    1,956

Thread Display Options

Loading...